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Background Countries in the World Health Organization (WHO) European Region differ in terms of the COVID-19
vaccine supply conditions. We evaluated the health and economic impact of different age-based vaccine prioritisation
strategies across this demographically and socio-economically diverse region.
Methods We fitted age-specific compartmental models to the reported daily COVID-19 mortality in 2020 to inform
the immunity level before vaccine roll-out. Models capture country-specific differences in population structures, con-
tact patterns, epidemic history, life expectancy, and GDP per capita.
We examined four strategies that prioritise: all adults (V+), younger (20-59 year-olds) followed by older adults (60+)
(V20), older followed by younger adults (V60), and the oldest adults (75+) (V75) followed by incrementally younger age
groups. We explored four roll-out scenarios (R1-4) — the slowest scenario (R1) reached 30% coverage by December
2022 and the fastest (R4) 80% by December 2021. Five decision-making metrics were summarised over 2021-22: mor-
tality, morbidity, and losses in comorbidity-adjusted life expectancy, comorbidity- and quality-adjusted life years, and
human capital. Six vaccine profiles were tested — the highest performing vaccine has 95% efficacy against both infec-
tion and disease, and the lowest 50% against diseases and 0% against infection.
Findings Of the 20 decision-making metrics and roll-out scenario combinations, the same optimal strategy applied to all
countries in only one combination; V60 was more or similarly desirable than V75 in 19 combinations. Of the 38 countries
with fitted models, 11-37 countries had variable optimal strategies by decision-making metrics or roll-out scenarios. There
are greater benefits in prioritising older adults when roll-out is slow and when vaccine profiles are less favourable.
Interpretation The optimal age-based vaccine prioritisation strategies were sensitive to country characteristics, deci-
sion-making metrics, and roll-out speeds. A prioritisation strategy involving more age-based stages (V75) does not
necessarily lead to better health and economic outcomes than targeting broad age groups (V60). Countries expecting
a slow vaccine roll-out may particularly benefit from prioritising older adults.
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Evidence before this study
We searched PubMed andmedRxiv for articles published in
English from inception to 9 June 2021, with the search
terms: (“COVID-19” OR “SARS-CoV-2”) AND (“priorit*) AND
(“model*”) AND (“vaccin*”) and identified 66 studies on vac-
cine prioritization strategies. Of the 25 studies that com-
pared two or more age-based prioritisation strategies, 12
found that targeting younger adults minimised infections
while targeting older adults minimised mortality; an addi-
tional handful of studies found similar outcomes between
different age-based prioritisation strategies where large
outbreaks had already occurred. However, only two studies
have explored age-based vaccine prioritisation using mod-
els calibrated to observed outbreaks in more than one
country, and no study has explored the effectiveness of
vaccine prioritisation strategies across settings with differ-
ent population structures, contact patterns, and outbreak
history.
Added-value of this study
We evaluated various age-based vaccine prioritisation
strategies for 38 countries in the WHO European Region
using various health and economic outcomes for deci-
sion-making, by parameterising models using observed
outbreak history, known epidemiologic and vaccine
characteristics, and a range of realistic vaccine roll-out
scenarios. We showed that while targeting older adults
was generally advantageous, broadly targeting every-
one above 60 years might perform better than or com-
parably to a more detailed strategy that targeted the
oldest age group above 75 years followed by those in
the next younger five-year age band. Rapid vaccine roll-
out has only been observed in a small number of coun-
tries. If vaccine coverage can reach 80% by the end of
2021, prioritising older adults may not be optimal in
terms of health and economic impact. Lower vaccine
efficacy was associated with greater relative benefits in
prioritising older adults.
Implication of all the available evidence
COVID-19 vaccine prioritization strategies that require more
precise targeting of individuals of a specific and narrow age
range may not necessarily lead to better outcomes com-
pared to strategies that prioritise populations across
broader age ranges. In the WHO European Region, prioritis-
ing all adults equally or younger adults first will only opti-
mise health and economic impact when roll-out is rapid,
which may raise between-country equity issues given the
global demand for COVID-19 vaccines.Introduction
The COVID-19 pandemic poses unprecedented chal-
lenges to public health, health systems and economies
globally. While non-pharmaceutical interventions
(NPIs, e.g. physical distancing) have effectively miti-
gated COVID-19 transmission,1 extraordinary effort and
resources have also been committed to developing and
rolling out COVID-19 vaccines.2 These global efforts
have led to successful vaccine development at an
unprecedented speed.
Some countries have signed bilateral advanced pur-
chasing agreements with vaccine manufacturers to
independently procure enough vaccine doses to cover
significant proportions of their populations. Many low-
and middle-income countries (LMICs) do not have the
resources for such an option.3 Globally coordinated
efforts to roll out COVID-19 vaccines are required to
achieve equitable vaccine distribution and control the
COVID-19 pandemic.
The global initiative “COVID-19 Vaccines Global
Access” (COVAX) has been set up to ensure equitable
vaccine access across countries 4. However, the speed at
which vaccines become available through COVAX is
constrained by production and logistical capacities. In
the interim vaccine distribution forecast published in
February 2021, COVAX was projected to deliver vac-
cines to cover approximately 3% of the total population
in the 145 COVAX facility participant countries by mid-
2021 and up to 20% of those populations by the end of
2021.4,5 For the World Health Organization (WHO)
European Region specifically, 16 of 53 Members States
may follow this projection as non-Advanced Market
Commitment (AMC) donors.4
Several additional challenges remain while deciding
on the optimal vaccine prioritisation strategies, besides
the diverse supply conditions. First, although there is
some evidence supporting prioritising older adults in
COVID-19 vaccine roll-out,6,7 the specific approach has
not been explored and could vary drastically.8 Second,
evidence on vaccine prioritisation strategies has pre-
dominantly been based on models fitted to data from
single or similar countries (predominantly non-LMICs).
The generalisability of such evidence to different social
contexts and epidemic history remains unclear. Third,
public health decision-makers need to consider the
trade-offs between public health outcomes. However,
most existing evidence only presents mortality and
infections as decision-making metrics.
To address these gaps in evidence, this work was
commissioned by WHO/Europe to inform the Euro-
pean Technical Advisory Group of Experts on Immuni-
zation (ETAGE) group for the regionalisation of thewww.thelancet.com Vol xx Month xx, 2021
ArticlesWHO Strategic Advisory Group of Experts on immuni-
zation (SAGE) Roadmap for prioritising population
groups for vaccines against COVID-19, based on the
regional specific context and published preliminary rec-
ommendations of selected national immunization tech-
nical advisory groups (NITAG) in the Region.
More specifically, this study evaluates different age-
based vaccine prioritisation strategies given different
vaccine supply conditions between 2021 and 2022 in
the WHO European Region. We aim to identify strate-
gies that maximise the health and economic impacts of
COVID-19 vaccines for each country, measured by five
decision-making metrics ((1) mortality, (2) cases, (3)
comorbidity-adjusted life expectancy (cLE) loss, (4)
comorbidity- and quality-adjusted life-years loss
(cQALY), and (5) human capital (HC) loss). These met-
rics allowed us to explore the trade-offs between mini-
mising COVID-19 mortality and morbidity. We
consider the known epidemiology of SARS-CoV-2 and
explore how demographic factors, government COVID-
19 response policy stringency, community mobility in
each country, and a wide range of vaccine characteristics
may affect the optimal vaccine allocation strategies in
the WHO European Region. Stakeholders to whom our
research is of great value and interest include vaccina-
tion and immunisation experts advising government
implementations, country-level policymakers focusing
on public health planning and health economics, and
vaccine programme managers.Figure 1.Model Framework
This figure describes the overall model framework of the study,
parameters based on existing knowledge” were used in both fittin
one of the stages as specified.
www.thelancet.com Vol xx Month xx, 2021Methods
Model framework
Our model framework consisted of two stages (Fig. 1).
The objective of the fitting stage was to estimate the pro-
portion of each age group in every country who were no
longer susceptible to SARS-CoV-2 by 01 January 2021.
The projection stage relied on the results from the fit-
ting stage, vaccine-related assumptions, health and eco-
nomic impact parameters, and projected mobility
changes related to expected public health and social
measures. Using these, we estimated the health and
economic impacts of different vaccine prioritisation
strategies between January 2021 and December 2022 in
each country.
For both stages, we used a previously described
COVID-19 compartmental dynamic transmission
model, CovidM.9 Equations describing the transmission
dynamics can be found in the Supplemental Methods
(p49-50). In brief, this model includes 16 age groups
defined by 5-year age bands (from 0-4 to 75+) and eight
compartments representing individuals who are: sus-
ceptible (S); exposed, i.e. infected but not yet infectious
(E); vaccinated (V); vaccinated, exposed and progressing
differently compared to unvaccinated and exposed indi-
viduals (Ev); infectious and showing no symptoms (i.e.
pre-clinical) although symptoms would eventually
appear (Ip); infectious and showing symptoms (i.e. clini-
cal) (Ic); infectious and showing no symptoms duringwhich consists of the fitting and projection stages. The “known




the course of infection (i.e. sub-clinical) (Is); recovered
from infection and protected by infection-induced
immunity (R) (Fig. 1). The model assumes individuals
in Is are 50% as infectious as those in Ip and Ic;9 age-spe-
cific clinical fractions (i.e. the proportion of exposed
individuals (E) that eventually progresses through Ip)
(range: 207%-691%);10 and age-specific susceptibili-
ties.10 COVID-19 mortality is modelled as the product
of age-specific infection counts (i.e. the sum of vacci-
nated and unvaccinated individuals progressing as E in
Fig. 1, See Supplemental Methods p50) and the age-
specific infection-fatality ratios (range: 67 per million
infections − 81 per hundred infections, monotonically
increasing by age).11
Models for each country were parameterised with
country-specific age structures (2020, Fig. 2, A, Supple-
mental Figure 1),12 contact patterns (using synthetic
contact matrices published in 2021 based on contact
survey data from 2004-2018, Fig. 2, B),13 local NPIs
stringency (January 2020-February 2021),14 community
mobility (February 2020-February 2021),15 observed
COVID-19 deaths (January 2020-December 2020),16
life expectancy (2019)17 and GDP per capita (2018 or
2019).18 Pathogen related parameters (e.g. incubation
period), vaccine profiles and characteristics (e.g. dura-
tion of vaccine-induced immunity) were assumed to be
common across the entire region. A table summarising
input variables and assumptions is presented in Supple-
mental Table 1.Fitting stage
Country-specific infection introduction dates and basic
reproduction numbers (R0s) were obtained by deter-
ministically fitting CovidM to daily reported COVID-19
mortality using maximum likelihood estimation (MLE)
and differential evolution global optimisation algo-
rithms assuming a Poisson likelihood function.19 The
infection introduction date was constrained to a 90-day
window before the first reported COVID-19 death in
each country. The R0s were constrained to the 1.5 to 5
range.20 We generated 500 stochastic realisations of the
outbreak trajectories over time to approximate the
uncertainty needed to evaluate the overall performance
of the fitting stage.
We used smoothed country-specific daily total
reported COVID-19 mortality (i.e. right-aligned seven-
day moving averages) in 2020 from Our World in Data
for the WHO European Region, most of which has been
collected from government reports.16 We fit the model
to mortality rather than cases because the latter may suf-
fer from greater underreporting due to limited testing
capacity.21 The definition of a COVID-19 death in this
dataset may vary slightly by country and over time and
may not always require a positive COVID-19 test.16 In
this study, we excluded countries with no (n = 1) or
sparse mortality data (<10 deaths/ day throughout thestudy period, n = 12) or with major changes in the
COVID-19 mortality case definition (n = 2).22 Of 53
members states of the WHO European Region, 38 were
included in the fitting stage. The countries excluded
and their corresponding rationales are listed in Supple-
mental Table 2.
Age-specific contact patterns (contacts per day by
age-group and country) were captured by country-spe-
cific synthetic contact matrices, which include informa-
tion from different contact settings: work, school, home,
and others.13 However, social contacts have deviated
from their pre-pandemic levels. Thus, we used Google
community mobility data (expressed as percentage devi-
ations from the pre-pandemic baseline established
using data from January 2020) to approximate the
changes in contact patterns in work and other settings
during the pandemic.15,23 Google community mobility
data is based on the movement history of users who
have signed into their Google account, turned on their
location history and used devices with Location Report-
ing turned on.15 The sample may not be representative
of the entire population. Additionally, social contacts in
the school setting were based on school-related NPI
stringency from the OxCGRT database.14 This variable
is originally categorical and ordinal, with values
between 0 (no measure) and 3 (require closing all lev-
els). This study assumes baseline school setting contacts
at level 0, no school-based contacts at level 3, and 50%
school-based contacts at level 1 or 2. Contacts at home
were assumed to stay unchanged compared to pre-pan-
demic periods. More information on mobility and NPI
stringency can be found in Supplemental Tables 3-5,
Supplemental Figures 2-6.
Evidence suggests COVID-19 mortality may have
been higher than reported in many countries.24 To
account for this, we repeated the fitting stage estimating
for an additional parameter— a country-specific tempo-
rally-invariant mortality underreporting rate, as a sensi-
tivity analysis.Projection stage
We assume that contact patterns (work and other) gradu-
ally recover over a year after March 2021 but never fully
return to pre-pandemic levels due to long-term policies
and behavioural changes (Supplemental Tables 3-5,
Supplemental Figures 2-6). More specifically, we
assumed that NPI intensity would gradually decrease as
vaccination is rolled out. We did not consider scenarios
where NPIs may be reinstated if further outbreaks occur
because the focus of our study was to evaluate vaccine
strategies rather than NPIs. Contact patterns in the
school setting followed school terms.26
We examined four possible roll-out scenarios: R1,
R2, R3 and R4 (Fig. 2, C), based on supply projections,
observed roll-out speed in different countries, and
potential challenges to achieving high uptake. R2www.thelancet.com Vol xx Month xx, 2021
Figure 2. Key inputs and assumptions.
(A) Example population age structure (for the United Kingdom, unit = million; those of other countries in the Region are presented in Supplementary Figure 1).12 (B) Example age-specific
within-population contact patterns (for the United Kingdom). 13 (C) Vaccine roll-out scenarios and the respective proportions of populations expected to be covered at different time points.
Note that under different vaccine roll-out scenarios, the starting time of vaccination programs may differ. Grey lines in the background represent observed country-level vaccine uptakes (of
the first dose) over time reported in the WHO European Region (as of October 2021). 25 (D) Vaccine prioritisation strategies. Hatched areas indicate when no vaccine was allocated. (E) Vaccine

















Articlesresembles the projected roll-out projections under
COVAX.4,5 In R1, vaccine roll-out is slower and final
uptake lower compared to R2. Contributors to relatively
slow roll-out speeds (such as in R1) may include vaccine
production delay and logistical challenges in delivering
vaccines. R1 and R2 both start from 01 March 2021.27
R4 resembles the trajectories of the rapid adopters of
the region.25 R3 achieves the same coverage as R4 but at
a slower pace. R3 and R4 both start from 01 January
2021.25 In the WHO European Region, as of August
2021, 25 countries have rolled out vaccination at a rate
equal to or greater than R4, 14 countries at a rate
between R3 and R4, nine countries at a rate between R1
and R3, and the remaining five countries have not yet
reported vaccine uptake.25
We examined four vaccine prioritisation strategies
(Fig. 2, D). In V+, the entire population aged 20+ years
received vaccines simultaneously. In strategy V20,
younger adults (20-59 year-olds) received vaccines
before older adults (60+ year-olds). In both V60 and
V75, older adults (60+ year-olds) were vaccinated first;
however, in V60, they were all vaccinated simulta-
neously. In V75, age groups were prioritised in 5-year
age bands, starting from those above 75 years of age.
The vaccine roll-out among age groups above 60
years was considered complete when uptake reached
90%, and among age groups between 20 and 59 years,
it was considered complete when uptake reached 70%.
These targets are consistent with optimistic roll-out
objectives and intended vaccine uptake observed in the
WHO European Region.2,28 We additionally explored
conditions where vaccine uptake thresholds were lower
(e.g. due to vaccine hesitancy; 29 “lower uptake targets”
were 80% for those above 60 and 65% for 20-59 year-
olds; “extremely low uptake targets” were 60% for those
above 60 and 45% for 20-59 year-olds) (see Supplemen-
tal Methods, p53 for rationale) and when adolescents
(10-19 year-olds) become eligible for the vaccines (while
assuming same uptake targets as younger adults, see
Supplemental Methods p54 for rationale).
There is still considerable uncertainty around the
immunity against SARS-CoV-2. In this study, we
assumed a 14-day delay between vaccination (i.e. receiv-
ing the vaccine) and immunisation (i.e. becoming pro-
tected by the vaccine).30 Based on a recent cohort
study,31 we assumed that protection gained from natural
SARS-CoV-2 infection would wane exponentially with a
mean duration of 3 years. Evidence on the duration of
vaccine-induced immunity has been limited. In this
study, we conservatively assumed that vaccines would
wane exponentially with a mean duration of 52 weeks,
potentially due to factors such as vaccine escape. We
additionally included a sensitivity analysis assuming a
mean duration of vaccine-induced immunity of 3 years,
consistent with that of natural immunity.32
Infection-blocking and disease-reducing mecha-
nisms of vaccines were both modelled. As baselinevaccine efficacy (VE), we assume that vaccination pre-
vents 95% of infections and diseases based on the high-
est performing vaccines in clinical trials and post-
introduction observational data.30,32,33 Additionally, we
explored a range of vaccine profiles (see Fig. 2, E) to
investigate the impact of vaccine performance on opti-
mal vaccine prioritisation strategies. Countries may
receive a range of vaccine products,32 which in turn
have different VE estimates depending on local SARS-
CoV-2 variants. The highest performing vaccine (i.e.
profile 1) resembles the Pfizer-BioNTech COVID-19 vac-
cine; profiles 3-4 resemble AstraZeneca’s COVID-19
vaccine.32 The worst performing vaccine profile (profile
6) has 50% efficacy against diseases and does not pro-
tect against infection. Such a profile could correspond
to the performance of some currently available vaccines
against certain variants of concern (VOCs) with high
vaccine escape potential. A sensitivity analysis was con-
ducted incorporating an additional 50% increase in
pathogen transmissibility since April 2021 to further
account for possible VOC characteristics.32,34
We used an ordinal logistic regression model to
explore whether the optimal vaccine prioritisation strat-
egies identified are associated with country-specific
characteristics such as population size, age structure,
contact patterns, the proportions of non-susceptible
individuals by 01 January 2021, and roll-out scenario.
To reduce collinearity, when a pair of variables are
strongly associated with each other (Pearson’s correla-
tion > 0.7), we only keep one variable of the pair that
has smaller correlations with other variables considered
(outside the pair).Outcomes
We assessed the impact of different vaccine prioritisa-
tion strategies in each country using the projected
cumulative measure of five health and economic deci-
sion-making metrics summarised over 01 January 2021
— 31 December 2022: (1) mortality counts, (2) case
counts, (3) comorbidity-adjusted life expectancy (cLE)
loss, (4) comorbidity- and quality-adjusted life years
(cQALY) loss, and (5) value of human capital (HC) loss.
The optimal strategy minimises these outcomes. Since
the top-ranking strategies may have similar effects, we
additionally calculated the regional totals for each health
and economic metric when one strategy is applied to the
entire region. For direct health outcomes, we focused
only on (1) mortality and (2) cases. The method used to
calculate COVID-19 mortality is described above. Pro-
jected COVID-19 cases are calculated by summing all
infected individuals progressing through Ic in Fig. 1 (i.
e. all symptomatic infections). We did not estimate for
hospitalisations and intensive care unit (ICU) admis-
sion, as they rely on factors such as severity and health-
care system capacity, which vary by country and over
time.35 We briefly define cLE, cQALY, and HC belowwww.thelancet.com Vol xx Month xx, 2021
Articlesand provide more details on their values in Supplemen-
tal Figures 7-9 and on their corresponding loss func-
tions in Supplemental Methods p51-52.
Life expectancy is the number of years an individual
would be expected to live had they not died prema-
turely.17 In the context of the COVID-19 pandemic, we
calculate the cLE by assuming a 50% increase in the
standardised mortality ratio (defined as how given
comorbidity may increase the risk of dying).36 The cLE
is country- and age-specific.
The cQALY is similar to the cLE but weigh the years
someone is alive based on their health-related quality of
life.37 The cQALY loss due to premature COVID-19
mortality was calculated using the average age-specific
population norms available for seven European coun-
tries and country-specific life expectancies, assuming
the QALY norms to be the same in other countries in
the WHO European Region.38 We estimated that each
symptomatic COVID-19 case leads to the loss of 0.0307
QALYs, which incorporates detriments due to non-hos-
pitalised illness episodes, hospitalisations, intensive-
care treatment, and “long COVID” (parameterised
using UK data, see Supplemental Methods p51-52).
Short-term vaccine side effects were assumed to occur
at 50% probability and to lead to a loss of 1 quality-
adjusted life day per vaccinee.39,40
The HC method weighs the number of life-years
someone loses by the country-specific GDP per capita
as a proxy for the value of that individual’s lost lifetime
productivity. These values are not adjusted for age or
sex since there is growing consensus that doing so
undervalues unpaid labour.41 We used the World Bank’s
country-level GDP per capita estimates.42
The analyses were conducted using R (4.0.4).43 An R
Shiny application is available at https://cmmid-lshtm.
shinyapps.io/demo/ to enable users to explore addi-
tional values for parameters such as roll-out speed, vac-
cination program starting date, and final up takes not
explored in this study.Role of funding source
The funders of the study had no role in study design;
data collection, analysis, and interpretation; preparation
of the manuscript; or the decision to publish.Results
Model fitting
The results of the fitting process for Georgia, Hungary
and the United Kingdom are shown in Fig. 3, A-C.
These were chosen as representatives of countries with
daily COVID-19 mortality in tens, hundreds, to thou-
sands, respectively. Results for all other countries are in
our Zenodo archive.44
We found that the inferred infection introduction in
most countries occurred in January 2020 (n = 38, IQR:www.thelancet.com Vol xx Month xx, 202125 December 2019, 14 January 2020) (Supplemental
Figure 10). The median R0 estimate was 167 (n = 38,
IQR: 158, 185) (Supplemental Figure 11). These esti-
mates are relatively low compared to existing litera-
ture,45 possibly due to NPIs that are not fully captured
by the intensity of mobility and contact patterns (e.g.
mask-wearing). Using these inferred parameters, we
estimated the median proportion of individuals no lon-
ger susceptible to SARS-CoV-2 by 01 January 2021 to be
1309% (n = 38, IQR: 694%, 2163%) (Fig. 3, D).Optimal prioritisation strategies
We observed substantial differences in the optimal vac-
cine prioritisation strategy. Of 38 countries with fitted
models, 7, 16, 27, and 22 countries have consistent opti-
mal strategies across decision-making metrics within
R1, R2, R3, and R4, respectively. Only one of the 38
countries with fitted models have the same optimal
strategy across decision-making metrics and across roll-
out scenarios. Of the 20 decision-making metric and
roll-out scenario combinations (n = 20 = 5 metrics £ 4
scenarios), only one identified the same optimal strategy
across the entire region - while minimising morbidity
under R1, V20 is the optimal strategy for all countries
with fitted models.
Under R1 and R2, in most countries, the optimal
strategy is V75 to minimise COVID-19 deaths and V20
to minimise COVID-19 cases (Fig. 4 (a-b), (e-f)). Under
R1 and based on cLE, cQALY or HC losses, most coun-
tries had V60 as their optimal strategy, although overall
the performances all strategies were similar when
applied to the entire region, leading to 3-7% (range,
n = 12 = 4 strategies £ 3 metrics) more losses compared
to when local optimal strategies were used (Fig. 4, (i),
(m), (g)). Under R2, although there were a comparable
number of countries with V+, V20 and V60 as their
optimal strategy based on cLE, cQALY and HC losses, V
+ was the best performing strategy when applied to the
entire region (Fig. 4, (j), (n), (r)).
Under R3, V+, V60 and V75 have roughly equal per-
formance when applied to the entire region regardless
of metric (Fig. 4, (c), (g), (k), (o), (s)), leading to an 8-
13% (range, n = 15, 3 strategies £ 5 metrics) increase
compared to when the optimal strategy for each country
was used instead using all metrics. However, under R4,
not prioritising by age (V+) becomes the optimal strat-
egy in most countries (Fig. 4, (d), (h), (l), (p), (t)). Pro-
portions of countries and populations by optimal
strategies, roll-out scenarios, and decision-making met-
rics are presented in Supplemental Tables 6-7. Overall,
V60 performs better or comparably to V75 in 19 of 20
decision-making metrics and roll-out scenario combina-
tions.
The results of the ordinal logistic regression model
show that the only factors that were significantly associ-
ated (with type I error rate < 0.05) with the optimal7
Figure 3. Results of the fitting stage
(A-C) Comparisons between observed (blue line) and predicted COVID-19 deaths using a deterministic realisation based on fitted parameters (black line) and 500 stochastic outbreak real-
isations based on the same fitted parameters (grey lines) in Georgia, Hungary, and the United Kingdom. (D) The estimated proportions of individuals no longer susceptible (non-susceptible)
to SARS-CoV-2 infection on 01 January 2021. Age-specific immunity level estimates were weighted by population age structure while calculating the country-level immunity levels. Countries

















Figure 4. Optimal vaccine prioritisation strategies under different roll-out scenarios and decision-making metrics
Main panel — Optimal strategies across the WHO European Region that minimise COVID-19 deaths, cases, losses in comorbidity-adjusted life expectancy (cLE), comorbidity- and quality-
adjusted life-years (cQALY), and human capital (HC) as decision-making metrics. All decision-making metrics were summed over 01 January 2021-31 December 2022. Top right inserts within
each panel— y-axis: Difference in outcome (totalled over the region) when a given prioritisation strategy is used across the entire WHO European Region compared to if the optimal prioritisa-
tion strategy in each country is used (black) x-axis: ranking. Shapefiles are downloaded from Eurostat GISCO 46; countries marked by crosshatch patterns are those that were not included in

















Articlesvaccine prioritisation strategies were roll-out scenarios
(Supplemental Figure 12). Faster roll-out scenarios were
associated with having optimal strategies that target
younger or all adults. Additionally, there was weak evi-
dence (with type I error rate < 0.1) supporting the asso-
ciation between the intensity of adult to older adult
contact patterns with having optimal strategies that pri-
oritise older adults.
When the duration of vaccine-induced immunity is
longer than expected (i.e. three years), the advantage of
prioritising older adults tends to diminish (Supplemen-
tal Figure 13). A more transmissible VOC would make
the advantages of V60 and V75 under R1-R3 and of V20
under R4 even more universal within the WHO Euro-
pean Region (Supplemental Figure 14). After incorpo-
rating underreporting of COVID-19 mortality, we
estimated higher proportions of non-susceptible indi-
viduals than baseline scenarios. However, the optimal
vaccine allocation strategies for the entire region
remained broadly unchanged (Supplemental Figure 15,
inner panels).
The optimal prioritisation strategies could be sensitive
to the decision time frame (Supplemental Figure 16). The
time frame in the baseline analysis (i.e. with a time horizon
of December 2022) was decided following discussions with
stakeholders. Such a long time horizon was agreed on
because a shorter horizon would bias decisions against
those that may prevent outbreaks that occur later in 2022.
However, a time horizon beyond 2022 was decided against
because of the large uncertainty around viral evolution and
changes in human behaviour.
In our sensitivity analyses using lower vaccine uptake
thresholds, we showed that the optimal prioritisation strat-
egies stayed broadly unchanged (87% unchanged using
“lower uptake targets”, and 61% unchanged using
“extremely low uptake targets”, see Supplemental Figure
17-18). Lastly, ourmodel shows that vaccinating adolescents
with younger adults may bring additional health and eco-
nomic benefits in 5-18 of 38 countries while using V60
and 25-28 of 38 countries while using V75 (Supplemental
Table 8).Sensitivity analysis by vaccine characteristics
The optimal vaccine prioritisation strategy is sensitive to
the vaccine profile (Fig. 5). Under R1 and R2, using low
performing vaccines (i.e. profiles 5 and 6) is associated
with having optimal strategies that prioritise older
adults (i.e. V60 or V75) in terms of minimising deaths
and losses in cLE, cQALY and HC. Under R3, the num-
bers of countries optimised by using V60 or V75 are rel-
atively insensitive vaccine profiles across decision-
making metrics. Under R4, low performing vaccines
make V60 and V75 slightly more favourable than
before. Under both R3 and R4, lower vaccine perform-
ances are both associated with more countries opti-
mised by using V20 (except for Fig. 5, (h)) and lessusing V+. Stakeholders interested in country-specific
results should refer to Supplemental Figures 19-20.Discussion
Using a transmission model of SARS-CoV-2 fitted to
reported COVID-19 mortality data in the WHO Euro-
pean Region, this study evaluates different vaccine pri-
oritisation strategies under a range of possible vaccine
roll-out scenarios in a wide range of social and demo-
graphic contexts. We found that country characteristics
affect optimal vaccine prioritisation strategies. We also
found that age-based vaccine prioritisation strategies
with more stages do not necessarily perform better. A
two-stage approach that prioritises all older adults
(V60) consistently performs better than or comparably
to a five-stage approach that initially prioritises the old-
est age group and only extends to the next five-year age
group younger when vaccination goals of the last group
have been met (V75). The choice between V60 and V75
may not depend on the health and economic impact but
on context-dependent factors such as delivery feasibility.
When vaccine supply and delivery capacity are in
place to reach 80% coverage by the end of 2021, the
benefits of precisely targeting older adults diminish. Pri-
oritising older adults may be more valuable to countries
that expect a longer timeline for vaccine uptake to
increase (e.g. nearly half of the WHO European Region
Member States). These conclusions continue to hold
when in the scenario with a 50% more transmissible
VOC. These findings raise issues around within-country
and between-country health equity. Countries with suf-
ficient supplies of vaccines may find that they maximise
benefits domestically by offering vaccination without
any age restrictions, as this could expedite roll-out.
However, there are insufficient supplies of COVID-19
vaccines globally to allow all countries to pursue such a
strategy. Increased supplies for one country come at the
expense of another.47
Evidence on infection-blocking and disease-reducing
VE of different vaccine products is emerging. Here, we
examined six different vaccine profiles, ranging from a
highly effective vaccine that prevents both infection and
disease at 95% to a vaccine that only prevents 50% of
disease and does not provide any protection against
infection. This range is designed around the vaccine
products currently licensed in the WHO European
Region. If vaccines become disease-reducing but not
infection-blocking, more countries expecting slower
roll-out may prioritise older adults (V60 or V75), given
that the severity of disease burden increases by age.Strengths and limitations
First, while existing literature focuses on evaluating
COVID-19 vaccine prioritisation in any city or country,
our study is the first to investigate the impact of suchwww.thelancet.com Vol xx Month xx, 2021
Figure 5. Optimal vaccine prioritisation strategies, given different vaccine profiles
Optimal strategy for each country and vaccine profile while minimising mortality, morbidity, and losses in comorbidity-adjusted
life expectancy (cLE), comorbidity- and quality-adjusted life-years (cQALY), and human capital (HC) for 38 countries in the WHO Euro-
pean Region. All decision-making metrics have been summed over 01 January 2021-31 December 2022. Country-specific results are
in Supplemental Figures 19 and 20.
Articlesstrategies under different circumstances across a large
region. Through working with country-specific charac-
teristics (e.g. age structure, contact pattern, epidemic
history, roll-out speed), we have highlighted the value of
local evidence. Different age structures, contactwww.thelancet.com Vol xx Month xx, 2021patterns, and sizes of existing epidemics may affect the
health and economic impacts of vaccination prioritisa-
tion strategies.
Second, we built our analyses around realistic vac-
cine roll-out scenarios based on projecting the broad11
12
Articlespatterns in vaccine roll-out rates across the region.
Third, we evaluated a wide range of age-prioritisation
strategies, not only under different roll-out scenarios
but also at different supply levels (e.g. 3%, 20%, 50% or
80% coverage). The results inform policy recommenda-
tions, providing the necessary details for continuous
implementation. The models and analyses presented
here have benefited from continuous input since late
2020 from the WHO Regional Office for Europe and
technical advisors from many countries in the region.
Fourth, we included additional decision-making metrics
beyond mortality and morbidity, providing a more com-
prehensive assessment of the various trade-offs that
need to be considered between outcomes.48 Fifth, we
considered various vaccine profiles to account for uncer-
tainty around vaccine characteristics. Finally, new evi-
dence about vaccine action, changes in vaccine supply
constraints and the emergence of additional variants of
concern (VOCs) may necessitate re-evaluation. To facili-
tate this, we have developed an online tool to help
inform such policy decisions (available since the end of
2020).
We did not examine exposure risk- (e.g. highly con-
nected individuals) or occupation-based (e.g. healthcare
providers) vaccine prioritisation strategies. The evalua-
tion of these strategies requires parameters governing
their transmission risk (e.g. contact matrices by occupa-
tion, coverage, and effectiveness of personal protective
equipment), most of which are not currently available.
We did not project healthcare system outcomes such as
hospital bed and ICU occupancy as there are substantial
variations across countries and subnational regions and
overtime in patient pathways, healthcare capacity and
hospital organisation.35
The fitting stage is based on mortality data before
2021, i.e. before the start of vaccine roll-out and the
large-scale emergence of VOCs that are more transmis-
sible, more clinically severe, and potentially immune
escaping.32 To inform the level of population immunity
present before vaccination programmes started, we fit
models qualitatively to time series of death counts for
each country to reproduce the course of epidemics in
2020, hence approximately capturing immunity levels
when vaccination programs in the WHO European
Region started in early 2021. Work to extend the fitting
window into 2021 would be useful to address future pol-
icy questions. However, it would require vaccine prod-
uct-, age- and dose-specific uptake levels, country-
specific underreporting rates for cases as well as for
deaths (to address changes in infection fatality risks due
to vaccination and VOCs), and VOC-specific surveil-
lance data (adjust for testing intensity and account for
reporting bias), and updated mobility-to-contacts rela-
tionships. The fitting stage includes a country-specific
temporally invariant underreporting rate of COVID-19
mortality as a part of the sensitivity analysis. This rate
may be time-varying.49 However, incorporating timedependencies would likely make parameter identifica-
tion difficult.
The projection stage uses constant vaccine efficacy
values before December 2022, which may not remain
valid as VOCs spread, although we used a range of vac-
cine profiles that likely cover performance against the
most common variants in the WHO European Region
as of mid-2021.50 We modelled the vaccine in use as a
single-dose product with a 14-day delay between vaccina-
tion and effective protection. These assumptions may be
replaced by new evidence on VE and the immunity
development process as they emerge. Finally, we
assumed NPIs gradually return to near pre-pandemic
levels as vaccines roll out between March 2021 and
March 2022. We have not mechanistically captured
reactive rule based NPIs, such as workplace closure
when incidence exceeds a certain threshold, because
these rules differ widely across countries and over time.
In this study, we provide an important piece of evi-
dence to inform the decision-making processes for
designing age-based vaccine prioritisation strategies. In
practice, stakeholders involved in such processes may
need to consider additional pieces of evidence, such as
vaccine supply chain capacity and healthcare system
structure and capacity. From early 2021, Israel and Por-
tugal have adopted V60-type approaches, drawing lines
at 60 and 50 years respectively while prioritising older
adults. The United Kingdom and Germany have
adopted the V75-type approach, starting from individu-
als above 80 years old.8 Some European countries have
chosen not to prioritise by age at all.8Conclusion
In conclusion, we identified optimal age-based vaccine
prioritisation strategies under different vaccine roll-out
scenarios and vaccine effectiveness profiles at the coun-
try level in the WHO European Region. We showed that
the benefits of prioritising older adults were more evi-
dent for relatively slow vaccine roll-out scenarios. When
prioritising older adults, broadly targeting everyone
above 60 years consistently performed comparably or
better than targeting the oldest adults first followed by
the next younger five-year age group - the additional
stages does not lead to health or economic gains. Priori-
tising younger adults or not prioritising by age is only
beneficial when vaccines can be rolled out quickly (e.g.
reaching 80% of the population vaccinated in 1 year).Contributors
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